• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

    9/7/21 8:30:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIX alert in real time by email

    SAN JOSE, Calif., Sept. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today the appointment of Pamela D. Garzone, Ph.D., as Chief Development Officer.  Dr. Garzone will oversee Anixa's vaccine and therapeutic development programs and will report to the CEO.

    Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)

    "We are pleased to have Dr. Garzone join Anixa at this pivotal and exciting time for the company," stated Dr. Amit Kumar, President and CEO of Anixa Biosciences.  "Pam's clinical experience will be instrumental as we enter clinical trials with our preventative breast cancer vaccine and our ovarian cancer CAR-T treatment."

    Dr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development.  Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer.  She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech.  Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy.  She earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh.  She received her Ph.D. in Clinical Science from the University of Pittsburgh.  In 2019, she was awarded the Distinguished Alumnus of University of Pittsburgh School of Pharmacy.

    Dr. Garzone stated, "I am excited and honored to join the team at Anixa, as the company transitions from a pre-clinical company to a clinical company.  I am looking forward to helping advance Anixa's programs, especially the breast cancer vaccine which is about to enter clinical trials shortly." 

    About Anixa Biosciences, Inc.

    Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at www.anixa.com.

    Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

    Contact:

    Mike Catelani

    [email protected]

    408-708-9808

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-appoints-dr-pamela-garzone-as-chief-development-officer-301369447.html

    SOURCE Anixa Biosciences, Inc.

    Get the next $ANIX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANIX

    DatePrice TargetRatingAnalyst
    3/21/2025$10.00Buy
    Maxim Group
    12/23/2022$8.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ANIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

      Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine Platform Technology Addresses Substantial Unmet Need in Preventive Oncology with Multi-Billion Dollar Market Potential SAN JOSE, Calif., July 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,370,244 on July 29, 2025, covering key aspects of the Company's breast cancer vaccine technology. The patent protects novel methods of immunizing patients against breast cancer by administering an immunogenic composit

      7/24/25 8:00:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

      SAN JOSE, Calif., July 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025 covering key aspects of its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2), a promising target for ovarian cancer prevention and treatment.

      7/9/25 8:00:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

      Fourth cohort dose is three million CAR positive cells; thirty times higher than the first cohort dose SAN JOSE, Calif., June 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the fourth dosage cohort in the ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center ("Moffitt") under the direction of Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moff

      6/23/25 8:00:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baskies Arnold M bought $16,950 worth of shares (5,000 units at $3.39), increasing direct ownership by 4% to 125,000 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/21/25 8:30:06 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Titterton Lewis H Jr bought $31,400 worth of shares (10,000 units at $3.14), increasing direct ownership by 1% to 943,334 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/15/25 6:03:41 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kumar Amit bought $15,750 worth of shares (5,000 units at $3.15), increasing direct ownership by 0.88% to 574,925 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/14/25 8:40:10 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Anixa Biosciences Inc.

      10-Q - Anixa Biosciences Inc (0000715446) (Filer)

      5/28/25 4:20:30 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Anixa Biosciences Inc (0000715446) (Filer)

      3/21/25 4:15:30 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Anixa Biosciences Inc.

      10-Q - Anixa Biosciences Inc (0000715446) (Filer)

      3/11/25 4:20:21 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Anixa Biosciences with a new price target

      Maxim Group initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $10.00

      3/21/25 8:14:33 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Anixa Biosciences with a new price target

      Chardan Capital Markets initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $8.00

      12/23/22 7:26:43 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Anixa Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $11.00

      4/12/21 6:30:29 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baskies Arnold M bought $16,950 worth of shares (5,000 units at $3.39), increasing direct ownership by 4% to 125,000 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/21/25 8:30:06 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Titterton Lewis H Jr bought $31,400 worth of shares (10,000 units at $3.14), increasing direct ownership by 1% to 943,334 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/15/25 6:03:41 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kumar Amit bought $15,750 worth of shares (5,000 units at $3.15), increasing direct ownership by 0.88% to 574,925 units (SEC Form 4)

      4 - Anixa Biosciences Inc (0000715446) (Issuer)

      7/14/25 8:40:10 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

      SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone, Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming Phase 2 breast cancer vaccine clinical trial. Suyasha Gupta is

      10/7/24 8:30:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja

      Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube. In the "Target: Cancer

      5/6/24 8:05:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

      SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board. Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most important

      4/18/24 8:20:00 AM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Financials

    Live finance-specific insights

    See more
    • Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

      – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and well tolerated – – Conference call to commence today at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.

      12/6/23 6:00:00 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

      – Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.

      12/6/23 4:05:00 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Anixa Biosciences Inc.

      SC 13D - Anixa Biosciences Inc (0000715446) (Subject)

      5/3/24 1:31:16 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Anixa Biosciences Inc. (Amendment)

      SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)

      1/16/24 5:29:43 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

      SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)

      9/3/21 4:15:28 PM ET
      $ANIX
      Biotechnology: Pharmaceutical Preparations
      Health Care